Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2018 now is available at the company’s website: www.medivir.com
2018 was transformative year for Medivir. We managed to successfully move the projects in our clinical portfolio forward. We also decided on an increased focus on the further development of our clinical portfolio. This resulted in a reorganization where the company’s administration and its activities in preclinical research were reduced and Medivir could enter 2019 with a slimmed organization that has a clear focus on the exciting clinical projects.
This and much more can be found in Medivir's Annual Report for 2018, published today at www.medivir.com.
For further information, please contact:
Lotta Ferm, Interim CFO Medivir AB, phone: +46 (0)73 125 1713.
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model and the drug development as well as the commercialization is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.